Alteplase treatment for acute stroke 2007: An effective therapeutic option at our disposal;Tratamiento con alteplasa en el infarto cerebral agudo 2007: Una opción terapéutica efectiva a nuestro alcance

Revista de Neurologia

Volumn 45, Issue 1, 2007, Pages 42-52

  Carneado Ruiz, Joaquín ^a,c   Saver, J L ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (Spain)

Author keywords

Health resources; Hemorrhage; Ischemic stroke; Randomized trials; Thrombolysis; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; ENVIRONMENT; EVOLUTION; HUMAN; MEDICAL INFORMATION; REVIEW; STROKE; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC THERAPY; HEALTH CARE ORGANIZATION; META ANALYSIS; PATHOLOGY; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED STATES;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HUMANS; META-ANALYSIS; NATIONAL INSTITUTES OF HEALTH (U.S.); RISK FACTORS; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES;

EID: 34948905328     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4501.2007307     Document Type: Review

References (80)

1. Murray CJ, López AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-42.
2. Kidwell CS, Liebeskind DS, Starkman S, Saver JL. Trends in acute ischemic stroke trials through the 20th century. Stroke 2001; 32: 1349-59.
3. Del Zoppo GJ. Thrombolysis: from the experimental findings to the clinical practice. Cerebrovasc Dis 2004; 17 (Suppl 1): 144-52.
4. Clarke RL, Cliffton EE. The treatment of cerebrovascular thrombosis and embolism with fibrinolytic agents. Am J Cardiol 1960; 30: 546-51.
5. Fletcher AP, Alkjaersig N, Lewis M, Tulevski V, Davies A, Brooks JE, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976; 7: 135-42.
6. Hanaway J, Torack R, Fletcher AP, Landau WM. Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke. Stroke 1976; 7: 143-6.
7. Meyer JS, Gilroy J, Barnhart ME, Johnson JF. Therapeutic thrombolysis in cerebral thromboembolism: randomized evaluation of intravenous streptokinase. In Millikan CH, Siekert RG, Whisnant JP, eds. Cerebral vascular diseases: Fourth Princeton Conference. New York: Grune & Stratton; 1965. p. 200-13.
8. Del Zoppo G, Zeumer H, Harker L. Thrombolytic therapy in stroke: possibilities and hazards. Stroke 1986; 17: 595-609.
9. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduced neurological damage after cerebral embolism. Science 1985; 230: 1289-92.
10. Del Zoppo GJ, Ferbert A, Otis S, Brückmann H, Hacke W, Zyroff J, et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke: a pilot study. Stroke 1988; 19: 307-13.
11. Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988; 19: 802-12.
12. Mori E. Fibrinolytic recanalization therapy in acute cerebrovascular thromboembolism. In Hacke W, Del Zoppo GJ, Hirschberg M, eds. Thrombolytic therapy in acute ischemic stroke. Heidelberg: Springer; 1991. p. 137-46.
13. Hacke W, Zeumer H, Ferbert A, Brückmann H, Del Zoppo GJ. Intraarterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988; 19: 1216-22.
14. Del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32: 78-86.
15. NINDS rt-PA Stroke Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.
16. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, Von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-25.
17. Hacke W, Kaste M, Fieschi C, Von Kummer R, Dávalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-51.
18. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS Study: a randomised controlled trial: Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282: 2019-26.
19. Clark WM, Albers GW, Madden KP, Hamilton S, for the Thrombolytic Therapy in Acute Ischaemic Stroke Study Investigators. The rt-PA (alteplase) 0- to 6- hour Acute Stroke Trial, Part A (A027g). Results of a double-blind, placebo-controlled, multicentre study. Stroke 2000; 31: 811-6.
20. Del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators: Prolyse in Acute Cerebral Thromboembolism. Stroke 1998; 29: 4-11.
21. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial: Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282: 2003-11.
22. Candelise L, Aritzu E, Ciccone A, Ricci S, Wardlaw J, Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346: 1509-14.
23. Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Besson G, et al, for the MAST Study Group. Termination of trial of streptokinase in severe acute ischaemic stroke. Lancet 1995; 345: 57.
24. Donnan G, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeill JJ, et al, for the Australian Estreptoquinasa Trial Investigators. Streptokinase in acute ischaemic stroke. Does time of therapy administration affect outcome? JAMA 1996; 271: 961-6.
25. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Dávalos A, Eliasziw M, et al, DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66-73 .
26. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, et al, MERCI Trial Investigators. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005; 36: 1432-8.
27. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al, SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-82.
28. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, et al. Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23: 632-40.
29. Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, et al. Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23: 641-5.
30. Ingall TJ, O'Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004; 35: 2418-24.
31. Wardlaw JM, Lindley RI, Lewis S. Thrombolysis for acute ischemic stroke: still a treatment for the few by the few. West J Med 2002; 176: 198-9.
32. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004; 61: 1066-70.
33. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999; 340: 1781-7.
34. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997; 28: 2119-25.
35. Hacke W, Donnan G, Fieschi C, Kaste M, Von Kummer R, Broderick JP, et al, ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-74.
36. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003; 3: CD000213.
37. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976-82.
38. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283: 1151-8.
39. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003; 34: 2847-50.
40. Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005; 172: 1307-12.
41. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment With Alteplase to Reverse Stroke (STARS) Study. JAMA 2000; 283: 1145-50.
42. Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 2001; 58: 2009-13.
43. Schmülling S, Grond M, Rudolf J, Heiss WD. One-year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke 2000; 31: 1552-4.
44. Koennecke HC, Nohr R, Leistner S, Marx P. Intravenous tPA for ischemic stroke: team performance over time, safety, and efficacy in a single-center, 2-year experience. Stroke 2001; 32: 1074-8.
45. Buchan AM, Barber PA, Newcommon N, Karbalai HG, Demchuk AM, Hoyte KM, et al. Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness. Neurology 2000; 54: 679-84.
46. Wang DZ, Rose JA, Honings DS, Garwacki DJ, Milbrandt JC. Treating acute stroke patients with intravenous tPA: the OSF Stroke Network experience. Stroke 2000; 31: 77-81.
47. Akins PT, Delemos C, Wentworth D, Byer J, Schorer SJ, Atkinson RP. Can emergency department physicians safely and effectively initiate thrombolysis for acute ischemic stroke? Neurology 2000; 55: 1801-5.
48. Egan R, Lutsep HL, Clark WM, Quinn J, Kearns K, Lockfeld A, et al. Open label tissue plasminogen activator for stroke: the Oregon experience. J Stroke Cerebrovasc Dis 1999; 8: 287-90.
49. Tanne D, Bates VE, Verro P, Kasner SE, Binder JR, Patel SC, et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. Neurology 1999; 53: 424-7.
50. Bravata DM, Kim N, Concato J, Krumholz HM, Brass LM. Thrombolysis for acute stroke in routine clinical practice. Arch Intern Med 2002; 162: 1994-2001.
51. López-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurrú C, Biller J. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 2001; 32: 12-6.
52. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM, for the Cleveland Clinic Health System Stroke Quality Improvement Team. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke 2003; 34: 799-800.
53. Smith RW, Scott PA, Grant RJ, Chudnofsky CR, Frederiksen SM. Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis. Acad Emerg Med 1999; 6: 618-25.
54. Heuschmann PU, Kolominsky-Rabas PL, Roether J, Misselwitz B, Lowitzsch K, Heidrich J, et al, German Stroke Registers Study Group. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 2004; 292: 1831-8.
55. Trouillas P, Von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke 2006; 37: 556-61.
56. Brown DL, Barsan WG, Lisabeth LD, Gallery ME, Morgenstern LB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med 2005; 46: 56-60.
57. Szoeke CE, Parsons MW, Butcher KS, Baird TA, Mitchell PJ, Fox SE, et al. Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust 2003; 178: 324-8.
58. Lindsberg PJ, Soinne L, Roine RO, Salonen O, Tatlisumak T, Kallela M, et al. Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke 2003; 34: 1443-9.
59. Dávalos A, Álvarez-Sabín J, Martí-Vilalta JL, Castillo J. Tratamiento intravenoso con activador del plasminógeno tisular en la isquemia cerebral aguda. Med Clin (Barc) 2003; 120: 1-5.
60. Saposnik G, Young B, Silver B, Di Legge S, Webster F, Beletsky V, et al. Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy: predictors and association with outcome. JAMA 2004; 292: 1839-44.
61. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Álvarez-Sabín J, et al, CLOTBUST Investigators. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004; 351: 2170-8.
62. Walters MR, Muir KW, Harbison J, Lees KR, Ford GA. Intravenous thrombolysis for acute ischaemic stroke: preliminary experience with recombinant tissue plasminogen activator in the UK. Cerebrovasc Dis 2005; 20: 438-42.
63. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al, Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37: 1810-5.
64. Dzialowski I, Pexman JH, Barber PA, Demchuk AM, Buchan AM, Hill MD; CASES Investigators. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry. Stroke 2007; 38: 75-9.
65. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002; 105: 1679-85.
66. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997; 28: 2109-18.
67. Larrue V, Von Kummer R, Del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997; 28: 957-60.
68. Larrue V, Von Kummer R, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator. A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32: 438-41.
69. Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG, et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology 2001; 57: 1603-10.
70. Hill MD, Rowley HA, Adler F, Eliasziw M, Furlan A, Higashida RT, et al, for the PROACT II investigators. Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS. Stroke 2003; 34: 1925-31.
71. Kidwell CS, Saver JL, Carneado J, Sayre J, Starkman S, Duckwiler G, et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002; 33: 717-24.
72. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107: 598-603.
73. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004; 35: 1671-6.
74. Neumann-Haefelin T, Hoelig S, Berkefeld J, Fiehler J, Gass A, Humpich M, et al, MR Stroke Group. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke 2006; 37: 2463-6.
75. Trouillas P, Derex L, Philippeau F, Nighoghossian N, Honnorat, Hanss M, et al. Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rTPA thrombolysis. A study in 157 cases. Stroke 2004; 35: 1323-8.
76. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2002; 1: CD000197.
77. Stroke Unit Trialists' Collaboration. Collaborative systematic review of the randomised trials of organized impatient (stroke unit) care after stroke. BMJ 1997; 314: 1151-9.
78. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001; 32: 1832-40.
79. Johnston SC, Fung LH, Gillum LA, Smith WS, Brass LM, Lichtman JH, et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke 2001; 32: 1061-8.
80. Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies. Stroke 2005; 36: 2311-20.